• 1. Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents
  Casey J. Maguire,Zhi Chen,Vani P. Mocharla,Madhavi Sriram,Tracy E. Strecker,Ernest Hamel,Heling Zhou,Ramona Lopez,Yifan Wang,Ralph P. Mason,David J. Chaplin,Mary Lynn Trawick,Kevin G. Pinney Med. Chem. Commun. 2018 9 1649
• 2. Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues
  Casey J. Maguire,Graham J. Carlson,Jacob W. Ford,Tracy E. Strecker,Ernest Hamel,Mary Lynn Trawick,Kevin G. Pinney Med. Chem. Commun. 2019 10 1445
• 3. 2-(3′,4′-Dimethoxybenzylidene)tetralone induces anti-breast cancer activity through microtubule stabilization and activation of reactive oxygen species
  Yashveer Gautam,Sonam Dwivedi,Ankita Srivastava,Hamidullah,Arjun Singh,D. Chanda,Jyotsna Singh,Smita Rai,Rituraj Konwar,Arvind S. Negi RSC Adv. 2016 6 33369
• 4. In(OTf)3-catalyzed intramolecular hydroarylation of α-phenylallyl β-ketosulfones – synthesis of sulfonyl 1-benzosuberones and 1-tetralones
  Meng-Yang Chang,Kai-Xiang Lai,Yu-Lun Chang RSC Adv. 2020 10 18231
• 5. In(OTf)3-catalyzed intramolecular hydroarylation of α-phenylallyl β-ketosulfones – synthesis of sulfonyl 1-benzosuberones and 1-tetralones
  Meng-Yang Chang,Kai-Xiang Lai,Yu-Lun Chang RSC Adv. 2020 10 18231

• Solvents and Organic Chemicals Organic Compounds Benzenoids Tetralins Tetralins
• Solvents and Organic Chemicals Organic Compounds Benzenoids Tetralins
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone

Introduction to 1,2,3,4-tetrahydronaphthalen-1-one (CAS No. 529-34-0)

1,2,3,4-tetrahydronaphthalen-1-one, identified by the Chemical Abstracts Service Number (CAS No.) 529-34-0, is a significant organic compound that has garnered considerable attention in the field of pharmaceutical chemistry and chemical biology. This bicyclic ketone derivative belongs to the tetralone class and serves as a versatile intermediate in synthetic chemistry. Its unique structural framework, featuring a partially hydrogenated naphthalene core with a ketone functional group at the 1-position, makes it a valuable scaffold for developing novel bioactive molecules.

The compound’s molecular structure consists of a seven-membered aromatic ring fused to a five-membered lactam ring, which contributes to its distinct chemical properties. These properties include moderate solubility in organic solvents such as dichloromethane and ethyl acetate, as well as its stability under standard laboratory conditions. The presence of the ketone group at the 1-position enhances its reactivity in various organic transformations, making it a preferred building block for medicinal chemists.

In recent years, 1,2,3,4-tetrahydronaphthalen-1-one has been extensively studied for its potential applications in drug discovery and development. Its structural motif is reminiscent of several natural products and pharmacophores found in therapeutic agents. For instance, derivatives of this compound have been explored as intermediates in the synthesis of nonsteroidal anti-inflammatory drugs (NSAIDs) and other therapeutic molecules targeting inflammatory pathways.

One of the most compelling aspects of 1,2,3,4-tetrahydronaphthalen-1-one is its role as a precursor in the synthesis of more complex heterocyclic compounds. Researchers have leveraged its reactivity to develop novel scaffolds that exhibit improved pharmacokinetic profiles and enhanced biological activity. For example, modifications at the 4-position of the tetralone ring have led to compounds with potent inhibitory effects on enzymes involved in metabolic disorders.

The pharmaceutical industry has shown particular interest in tetrahydronaphthalen-1-one derivatives due to their potential as kinase inhibitors. Kinases are enzymes that play critical roles in cell signaling pathways and are frequently targeted in anticancer therapies. By incorporating structural elements derived from 1,2,3,4-tetrahydronaphthalen-1-one, chemists have been able to design molecules that selectively inhibit aberrant kinase activity associated with various diseases.

Recent advances in computational chemistry have further enhanced the utility of CAS No. 529-34-0 in drug design. Molecular modeling studies indicate that tetralone derivatives can effectively interact with target proteins through multiple binding sites. This promiscuous binding capability has opened up new avenues for developing multitarget drugs that address complex diseases with a single therapeutic agent.

Moreover, the synthesis of 1,2,3,4-tetrahydronaphthalen-1-one has been optimized through various catalytic methods to improve yield and purity. Transition metal-catalyzed reactions have emerged as particularly effective strategies for constructing the tetralone core. These methods not only streamline the synthetic process but also allow for greater functional group tolerance during derivatization.

In academic research, CAS No. 529-34-0 continues to be employed as a benchmark compound for studying reaction mechanisms and developing new synthetic protocols. Its well-documented reactivity patterns provide chemists with a reliable framework for exploring novel transformations. Collaborative efforts between experimentalists and theoreticians have shed light on the electronic structure of tetralones and their interactions with biological systems.

The biocatalytic potential of tetrahydronaphthalen-1-one derivatives has also been explored recently. Enzymatic modifications of this scaffold have led to compounds with improved bioavailability and reduced toxicity profiles. Such findings underscore the importance of integrating enzymatic strategies into drug development pipelines alongside traditional synthetic approaches.

Looking ahead, the future applications of 1,2,3,4-tetrahydronaphthalen-1-one are likely to expand into emerging fields such as precision medicine and personalized therapeutics. Its structural versatility makes it an ideal candidate for generating libraries of compounds tailored to individual patient profiles. By leveraging high-throughput screening technologies alongside advanced synthetic methodologies, researchers can rapidly identify lead candidates for further optimization.

In conclusion,CAS No. 529-34-0 (1,2,3,4-tetrahydronaphthalen-1-one) remains a cornerstone compound in pharmaceutical chemistry with far-reaching implications for drug discovery and development. Its unique structural features combined with its broad applicability ensure its continued relevance in both academic research and industrial settings.

• 22531-06-2(7-Ethyl-1-tetralone)
• 5037-63-8(5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-1-one)
• 51015-28-2(8-methyltetralin-1-one)
• 29059-07-2(Naphthalenone,3,4-dihydro-)
• 1273651-37-8(1(2H)-naphthalenone, 3,4-dihydro-6-propyl-)
• 13621-25-5(5,7-Dimethyl-1-tetralone)
• 106949-28-4(1(2H)-Naphthalenone,7-acetyl-3,4-dihydro-)
• 19550-57-3(6,7-Dimethyl-1-tetralone)
• 58138-42-4(1(2H)-Naphthalenone, 6,7-diethyl-3,4-dihydro-)
• 22009-37-6(7-methyl-1,2,3,4-tetrahydronaphthalen-1-one)